Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Director | June 04, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECISION BIOSCIENCES INC
Report date June 04, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,826 |
Reported balance
After 2024-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-04 · Grant · Acquired 9,826 · Balance 9,826 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such shares. F2: The RSUs vest on the earlier to occur of (i) June 4, 2025 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such shares.
F2: The RSUs vest on the earlier to occur of (i) June 4, 2025 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dimension Therapeutics, Inc.
Report date November 07, 2017 · Filed November 07, 2017
Section 16 reporting ended · disclosed 2017-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 1
1 source rowRow 1 · 2017-11-07 · Disposition to issuer · Disposed 278,035 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx, in exchange for a cash payment of $6.00 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2026-01-31 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-07 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: This stock option, which vests in equal monthly installments over 48 months beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2027-01-31 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-07 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This stock option, which vests in equal monthly installments over 48 months beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx, in exchange for a cash payment of $6.00 per share.
F2: This stock option, which vests in equal monthly installments over 48 months beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
F3: This stock option, which vests in equal monthly installments over 48 months beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2024 Filed Jun 6, 2024 20:36 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 9,826 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-069934 · ownership.xml · derivative · entry 1 Wadsworth Samuel C. · CIK 0001653056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,826 Underlying: Common Stock · 9,826 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such shares. F2 · derivative.exercise_date: The RSUs vest on the earlier to occur of (i) June 4, 2025 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest on the earlier to occur of (i) June 4, 2025 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 04, 2024 Filed May 7, 2024 20:26 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 4,202 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-054584 · ownership.xml · derivative · entry 2 Wadsworth Samuel C. · CIK 0001653056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,202 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On May 4, 2023 the Reporting Person was granted RSUs. The RSUs vested in full on May 4, 2024. F4 · derivative.expiration_date: On May 4, 2023 the Reporting Person was granted RSUs. The RSUs vested in full on May 4, 2024. Read SEC document |
| May 04, 2024 Filed May 7, 2024 20:26 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 4,202 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-054584 · ownership.xml · nonDerivative · entry 1 Wadsworth Samuel C. · CIK 0001653056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on May 4, 2024. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · balance_after: On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split. Read SEC document |
| May 04, 2023 Filed May 8, 2023 20:15 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 126,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027928 · doc4.xml · derivative · entry 1 Wadsworth Samuel C. · CIK 0001653056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,075 Underlying: Common Stock · 126,075 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such shares. F2 · derivative.exercise_date: The RSUs vest on the earlier to occur of (i) May 4, 2024 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest on the earlier to occur of (i) May 4, 2024 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 10, 2022 Filed May 12, 2022 11:16 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantStock Option (Right to Buy) · Derivative | 156,951 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-22-028451 · doc4.xml · derivative · entry 1 Wadsworth Samuel C. · CIK 0001653056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,951 Underlying: Common Stock · 156,951 shares Expires 2032-05-09 F1 · derivative.exercise_date: The option vests on the earlier to occur of (i) May 10, 2023 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 21:17 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantStock Option (Right to Buy) · Derivative | 55,360 | $0.00 Strike: $9.66 | $0.00 |
DisclosureSEC source: 0001209191-21-063848 · doc4.xml · derivative · entry 1 Wadsworth Samuel C. · CIK 0001653056 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,360 Underlying: Common Stock · 55,360 shares Expires 2031-11-07 F1 · derivative.exercise_date: The option vests in 36 substantially equal monthly installments following November 8, 2021, such that the option shall be fully vested on November 8, 2024. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 17:12 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $1.90 | Not disclosed |
DisclosureSEC source: 0001209191-17-059634 · doc4.xml · derivative · entry 3 Wadsworth Samuel C. · CIK 0001653056 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2027-01-31 F3 · price: This stock option, which vests in equal monthly installments over 48 months beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F3 · derivative.exercise_date: This stock option, which vests in equal monthly installments over 48 months beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 17:12 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $7.14 | Not disclosed |
DisclosureSEC source: 0001209191-17-059634 · doc4.xml · derivative · entry 2 Wadsworth Samuel C. · CIK 0001653056 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-01-31 F2 · price: This stock option, which vests in equal monthly installments over 48 months beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F2 · derivative.exercise_date: This stock option, which vests in equal monthly installments over 48 months beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document |
| November 07, 2017 Filed Nov 7, 2017 17:12 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | Disposition to issuerCommon Stock | 278,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-059634 · doc4.xml · nonDerivative · entry 1 Wadsworth Samuel C. · CIK 0001653056 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx, in exchange for a cash payment of $6.00 per share. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 16:43 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-17-007660 · doc4.xml · derivative · entry 1 Wadsworth Samuel C. · CIK 0001653056 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-01-31 F1 · derivative.exercise_date: This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.